Meta-analysis of adverse events in recent randomized clinical trials for dimethyl fumarate, glatiramer acetate and teriflunomide for the treatment of relapsing forms of multiple sclerosis

International Journal of Neuroscience

Volumn 125, Issue 11, 2015, Pages 798-807

  Zagmutt, Francisco J ^a   Carroll, Cathryn A ^b  

^a EpiX Analytics   (United States)

^b TEVA Neuroscience   (United States)

Author keywords

direct comparison; indirect comparison; Multiple sclerosis; safety profile

Indexed keywords

FUMARIC ACID DIMETHYL ESTER; GLATIRAMER; TERIFLUNOMIDE; CROTONIC ACID DERIVATIVE; IMMUNOSUPPRESSIVE AGENT; TOLUIDINE DERIVATIVE;

ARTICLE; COMPARATIVE STUDY; HUMAN; META ANALYSIS; MULTIPLE SCLEROSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SHIFT TO THE LEFT; SHIFT TO THE RIGHT; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT; CHEMICALLY INDUCED; GASTROINTESTINAL DISEASE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PROCEDURES; TREATMENT OUTCOME;

CROTONATES; DIMETHYL FUMARATE; GASTROINTESTINAL DISEASES; GLATIRAMER ACETATE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TOLUIDINES; TREATMENT OUTCOME;

EID: 84942297646     PISSN: 00207454     EISSN: 15635279     Source Type: Journal    
DOI: 10.3109/00207454.2014.979982     Document Type: Article

References (29)

1. Fox RJ, Miller DH, Phillips JT, et al. Placebo-controlled phase 3 study of oral bg-12 or glatiramer in multiple sclerosis. N Engl J Med. 2012; 367(12): 1087-97.
2. Gold R, Kappos L, Arnold DL, et al. Placebo-controlled phase study of oral bg-12 for relapsing multiple sclerosis. N Engl J Med. 2012; 367(12): 1098-107.
3. O'Connor P, Wolinsky JS, Confavreux C, et al. Randomized trial of oral teriflunomide for relapsingmultiple sclerosis.NEngl J Med. 2011; 365(14): 1293-303.
4. Castro-Borrero W, Graves D, Frohman TC, et al. Current and emerging therapies in multiple sclerosis: A systematic review. Ther Adv Neurol Disord. 2012; 5(4): 205-20.
5. Smith B, Carson S, Fu R, et al. Drug class review: Diseasemodifying drugs for multiple sclerosis. Final Update 1 Report. Portland, Oregon 97239: Oregon Evidence-based Practice Center for theDrug Effectiveness Review Project2010 August 2010.
6. Weber MS, Menge T, Lehmann-Horn K, et al. Current treatment strategies for multiple sclerosis - efficacy versus neurological adverse effects. Curr Pharm Des. 2012; 18(2): 209-19.
7. Arnoldus JH, Killestein J, Pfennings LE, et al. Quality of life during the first 6 months of interferon-beta treatment in patients with ms. Mult Scler (Houndmills, Basingstoke, England) 2000; 6(5): 338-42.
8. Simone IL, Ceccarelli A, Tortorella C, et al. Influence of interferon beta treatment on quality of life in multiple sclerosis patients. Health Qual Life Outcomes. 2006; 4: 96.
9. O'Rourke KE, Hutchinson M. Stopping beta-interferon therapy in multiple sclerosis: An analysis of stopping patterns. Mult Scler. 2005; 11(1): 46-50.
10. Ruggieri RM, Settipani N, Viviano L, et al. Long-Term interferon-beta treatment for multiple sclerosis. Neurol Sci. 2003; 24(5): 361-4.
11. Ford C, Goodman A, Johnson K, et al. Continuous long-Term immunomodulatory therapy in relapsing multiple sclerosis: Results from the 15-year analysis of the us prospective open-label study of glatiramer acetate. Multiple Sclerosis. 2010; 16(3): 342-50.
12. Thone J, Ellrichmann G. Oral available agents in the treatment of relapsing remitting multiple sclerosis: An overview of merits and culprits. Drug Healthc Patient Saf. 2013; 5: 37-47.
13. Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions version 5.1.0 [updated march 2011]: The Cochrane Collaboration; 2011. Available at: www.cochranehandbook. org
14. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-Analyses: The prisma statement. PLoS Med. 2009; 6(7): e1000097.
15. Lu G, Ades AE. Combination of direct and indirect evidence in mixed treatment comparisons. StatMed. 2004; 23(20): 3105-24.
16. Spiegelhalter DJ, Abrams KR, Myles JP. Bayesian approaches to clinical trials and health-care evaluation. John Wiley &Sons, Ltd; 2004. Prior distributions; p. 139-80.
17. Salanti G, Ades AE, Ioannidis JP. Graphical methods and numerical summaries for presenting results from multipletreatment meta-Analysis: An overview and tutorial. J Clin Epidemiol. 2011; 64(2): 163-71.
18. Lunn DJ, Thomas A, Best N, et al. Winbugs - A bayesian modelling framework: Concepts, structure, and extensibility. Stat Comput. 2000; 10(4): 325-37.
19. R development core team. R: A language and environment for statistical computing. R foundation for statistical computing, vienna, austria. 2011. Available at: http://www.R-project. org
20. Panitch H, Goodin DS, Francis G, et al. Randomized, comparative study of interferon beta-1a treatment regimens in ms: The evidence trial. Neurology. 2002; 59(10): 1496-506.
21. Oh J, O'Connor PW. Safety, tolerability, and efficacy of oral therapies for relapsing-remitting multiple sclerosis. CNS Drugs. 2013; 27(8): 591-609.
22. Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: Results of a phase iii multicenter, doubleblind placebo-controlled trial. The copolymer 1 multiple sclerosis study group. Neurology. 1995; 45(7): 1268-76.
23. O'Connor P, Filippi M, Arnason B, et al. 250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: A prospective, randomised, multicentre study. Lancet Neurol. 2009; 8(10): 889-97.
24. Ioannidis JP, Evans SJ, Gotzsche PC, et al. Better reporting of harms in randomized trials: An extension of the consort statement. Ann Intern Med. 2004; 141(10): 781-8.
25. Boster A, Bartoszek MP, O'Connell C, et al. Efficacy, safety, and cost-effectiveness of glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis. Ther Adv Neurol Disord. 2011; 4(5): 319-32.
26. Ford CC, Johnson KP, Lisak RP, et al A prospective openlabel study of glatiramer acetate: Over a decade of continuous use in multiple sclerosis patients. Mult Scler (Houndmills, Basingstoke, England) 2006; 12(3): 309-20.
27. Hadjimichael O, Vollmer T, Oleen-Burkey M. Fatigue characteristics inmultiple sclerosis: The north american research committee on multiple sclerosis (narcoms) survey. Health Qual Life Outcomes. 2008; 6: 100.
28. Hutchinson M, Fox RJ, Havrdova E, et al. Efficacy and safety of bg-12 (dimethyl fumarate) and other disease-modifying therapies for the treatment of relapsing-remitting multiple sclerosis: A systematic review and mixed treatment comparison. Curr Med Res Opin 2013.
29. Khan O, Rieckmann P, Boyko A, et al. Three times weekly glatiramer acetate in relapsing-remitting multiple sclerosis. Ann Neurol. 2013; 73(6): 705-13.